US FDA accepts and grants priority review status to Alexion’s BLA for efzimfotase alfa to treat patients with hypophosphatasia aged 2 years and older: Cambridge, UK Saturday, Se ...

Alexion, AstraZeneca's Rare Disease's Biologics License Application (BLA) for efzimfotase alfa has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the ...

Alexion, AstraZeneca's Rare Disease's Biologics License Application (BLA) for efzimfotase alfa has been accepted and granted Priority Review by the US ...

AstraZeneca (AZN) said Friday the US Food and Drug Administration granted priority review to its Alexion unit's biologics license application for efzimfotase alfa to treat patient ...

EU Medicines Agency Panel Backs Indication Extension for AstraZeneca, Daiichi Sankyo's Breast Cancer Drug MT 09:05am AstraZeneca, Daiichi celebrate another recommended approval of Enhertu AN 08:38am ...

Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending its ...

Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has been recommended for approval in the European Union (EU) as an ...

An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...

Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit has put out ...